According to Zacks, “LA JOLLA PHARMACEUTICAL CO. is engaged in the research and development of therapeutic products for the treatment of autoimmune and inflammatory diseases. “
Separately, ValuEngine upgraded La Jolla Pharmaceutical from a hold rating to a buy rating in a report on Friday, December 25th.
La Jolla Pharmaceutical (NASDAQ:LJPC) last released its quarterly earnings data on Saturday, November 14th. The biopharmaceutical company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.11. The business had revenue of $9.07 million for the quarter. As a group, research analysts anticipate that La Jolla Pharmaceutical will post -1.68 earnings per share for the current fiscal year.
Hedge funds have recently bought and sold shares of the business. FMR LLC boosted its holdings in La Jolla Pharmaceutical by 3.3% during the first quarter. FMR LLC now owns 4,061,425 shares of the biopharmaceutical company’s stock worth $26,115,000 after purchasing an additional 128,074 shares during the last quarter. Morgan Stanley raised its holdings in La Jolla Pharmaceutical by 67.1% during the 1st quarter. Morgan Stanley now owns 638,120 shares of the biopharmaceutical company’s stock worth $2,680,000 after purchasing an additional 256,246 shares during the last quarter. California Public Employees Retirement System raised its holdings in La Jolla Pharmaceutical by 32.3% during the 2nd quarter. California Public Employees Retirement System now owns 42,200 shares of the biopharmaceutical company’s stock worth $180,000 after purchasing an additional 10,300 shares during the last quarter. Prudential Financial Inc. bought a new position in La Jolla Pharmaceutical during the 2nd quarter worth approximately $200,000. Finally, Goldman Sachs Group Inc. raised its holdings in La Jolla Pharmaceutical by 67.7% during the 2nd quarter. Goldman Sachs Group Inc. now owns 35,553 shares of the biopharmaceutical company’s stock worth $151,000 after purchasing an additional 14,358 shares during the last quarter. 70.97% of the stock is owned by institutional investors.
About La Jolla Pharmaceutical
La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock.
Featured Story: The Role of a Fiduciary and Individual Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.